Regeneron Pharmaceuticals Given Buy Rating at Goldman Sachs Group Inc. (REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “buy” rating reiterated by equities research analysts at Goldman Sachs Group Inc. in a research note issued to investors on Monday, Analyst Ratings Network.com reports. They currently have a $355.00 price target on the stock, up from their previous price target of $329.00. Goldman Sachs Group Inc.’s price target points to a potential upside of 16.15% from the company’s current price.
The analysts wrote, “REGN reported complete Phase 3 data for key eye drug, Eylea for a new indication (DME, vision loss due to diabetes) at the Retina Society conference. The data were in line with our expectations and we anticipate they will support approval for a broader label and drive uptake/growth.”
REGN has been the subject of a number of other recent research reports. Analysts at Piper Jaffray Cos. raised their price target on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $336.00 to $360.00 in a research note to investors on Monday. They now have an “overweight” rating on the stock. Separately, analysts at Oppenheimer raised their price target on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $300.00 to $310.00 in a research note to investors on Monday. They now have an “outperform” rating on the stock. Finally, analysts at TheStreet reiterated a “buy” rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note to investors on Thursday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and sixteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $273.42.
In other Regeneron Pharmaceuticals news, Chairman P Roy Vagelos sold 145,356 shares of the company’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $302.86, for a total value of $44,022,518.16. Following the completion of the transaction, the chairman now directly owns 65,759 shares in the company, valued at approximately $19,915,771. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 2.66% during mid-day trading on Monday, hitting $313.77. 636,497 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a one year low of $136.13 and a one year high of $311.00. The stock’s 50-day moving average is $265.3 and its 200-day moving average is $240.4. The company has a market cap of $30.655 billion and a price-to-earnings ratio of 40.41.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $1.73 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.92 by $0.81. The company had revenue of $458.00 million for the quarter, compared to the consensus estimate of $470.63 million. During the same quarter in the previous year, the company posted $0.90 earnings per share. The company’s revenue for the quarter was up 50.5% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals will post $3.50 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.